

MEMBRANE, FILTRATION MODULE AND METHOD FOR  
THE SEPARATION OF BIOMOLECULES FROM A LIQUID

This is a 371 of PCT/EP 2003/006564 filed 21 June 2003 and claims priority  
5 of DE 102 33 542.7 filed 23 July 2002.

## BACKGROUND OF THE INVENTION

Spherical carriers in the form of gels containing affinity ligands have been employed for a long time in many areas of biotechnology for purification and separation of 10 many different types of biomolecules. An example of such an application is the use of affinity ligands based on an agarose gel, commercially available in matrices such as aqueous suspensions or in lyophilized form. A persistent problem with such matrices containing affinity ligands is that it is difficult if not impossible to dry the matrices once they have become swollen in an aqueous medium because the small gel spheres are irreversibly 15 damaged during drying. Preservation and transport of such gels thus presents a considerable logistical problem.

From EP 0 787 523 A1 it is known that ligands of a carrier material can be coupled for separation of substances having an affinity for the ligands. The function of the ligands is to bind a single target substance or even an entire class of substances which 20 specifically adsorb to the ligands. It is further known from DE 196 17 775 A1 that membrane adsorbers or membranes can carry ligands which are capable of interacting with at least one substance in a liquid phase. The transport of the liquid phase through the membrane occurs in this case convectively due to a pressure differential. A chief drawback of such known separations of biomolecules is that the presence of water moisture in the carrier or membrane 25 involves the risk of microbial attack, thereby requiring the addition of preservatives. But at the same time, the carriers or membranes tend to dry out, which drying must be suppressed with complicated procedures in order to prevent loss of the bioactivity of the ligands.

A primary object of the present invention is therefore to provide membranes for separation of biomolecules from a fluid by means of affinity ligands that permits 30 elimination of complicated and costly wet storage of the membranes.

## BRIEF SUMMARY OF THE INVENTION

The foregoing object is achieved by the present invention, which allows dry storage of the membrane with the affinity ligand, yet retains the activity of the affinity ligand. Because the membrane can be stored practically without a significant loss of activity, storage and transportation costs can be significantly reduced and the separation of biomolecules is simplified.

There are essentially three aspects to the invention: (1) a microporous membrane infused with an affinity ligand capable of interacting with at least one type of biomolecule in a fluid; (2) a filtration module for the separation of biomolecules from a fluid, comprising a housing and at least one membrane of the type noted in (1); and (3) a method for the separation of biomolecules from a fluid by one or more membranes of the type noted in (1) or by a filtration module of the type noted in (2).

## BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of an exemplary filtration module of the invention with a single membrane in a housing.

FIG. 2 is a schematic of an exemplary filtration module of the invention with several membranes arranged in a series in a housing.

FIG. 3 a schematic of an exemplary filtration module of the invention with membranes arranged in several layers in a housing.

## DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Surprisingly, it has been found that membranes charged with affinity ligands such as proteins can be stored dry for a relatively long period of time without a loss of activity. A particularly suitable class of microporous membranes of this type is that which is commercially available from Sartorius AG of Göttingen, Germany under the trade name of Sartobind®. The term "dry" as used herein should be understood as relating to membranes or membrane bodies whose pore volume is substantially filled with air. This does not exclude those cases where the inner surface of the pores is covered with a highly volatile organic substance.

Suitable membranes are polymeric microporous membranes such as cellulose acetate (CA), cellulose nitrate (CN), polyamide, polyether sulfone (PES), polypropylene (PP)

and polyvinylidene fluoride (PVDF). The diameter of the pores for such membranes should be from 0.01 to 15  $\mu\text{m}$ , preferably from 0.2 to 5  $\mu\text{m}$ . The thickness of such membranes is from 100 to 500  $\mu\text{m}$ , preferably from 200 to 300  $\mu\text{m}$ . Such membranes are preferably chemically activated, so that the affinity ligands can be chemically coupled thereto.

5 However, physical binding of the affinity ligands to the membranes is also possible. In a preferred embodiment, the membrane of the invention is impregnated with glycerine, which aids in preventing damage to the membrane's microporous structure during the drying process.

10 Adsorptive affinity ligands are well known to persons skilled in the art, and include the following:

- thiophiles;
- hydrophobes with various chain lengths and configurations;
- reversed phase ligands;
- dyes, including reactive dyes;
- 15 - low molecular weight charged or non-charged organic molecules;
- amino acids and analogs thereof;
- coenzymes, cofactors and analogs thereof;
- substrates and analogs thereof;
- endocrine and exocrine substances such as hormones and substances having an effect similar to that of hormones and analogs thereof;
- 20 - enzyme substrates, enzyme inhibitors and analogs thereof;
- fatty acids, fatty acid derivatives, conjugated fatty acids and analogs thereof;
- nucleic acids, including DNA, RNA and analogs and derivatives thereof;
- 25 - monomers and analogs and derivatives thereof;
- polymers and oligopolymers and analogs and derivatives thereof;
- high molecular weight carbohydrates, linear or branched chain and substituted or unsubstituted;
- 30 - glycolic conjugates, such as
  - heparin;
  - amylose, cellulose;

- chitin, chitosan;
- lignin;
- and monomers, oligomers, and derivatives and analogs thereof;
- high molecular weight ligands such as
  - proteins and oligomers, subunits and parts thereof;
  - peptides, polypeptides and analogs and derivatives thereof;
  - lectine;
  - antibodies and parts thereof;
  - fusion proteins; and
  - haptenes;
  - enzymes and subunits and parts thereof;
  - structural proteins;
  - receptors and parts thereof;
  - xenobiotics;
- pharmaceuticals and pharmaceutically active substances;
- alkaloids;
- antibiotics; and
- biomimetic substances.

In another preferred embodiment of the invention, selective separation of different biomolecules can be achieved by using a plurality of membranes having affinity ligands coupled thereto. Moreover, the types of membranes can be adjusted in a relatively simple manner, depending on the relevant separation problem. The membranes can be arranged in a housing in multiple layers and can also be arranged serially in single housing chambers or in different housings.

Another aspect of the invention is to provide an efficient and cost-effective method for the membrane separation of biomolecules from a fluid, which is possible without the need for complicated wet storage and transport of the membranes used. The method comprises the following steps:

- (a) coupling at least one affinity ligand to the separation membrane in a solution;
- (b) washing the separation membrane of step (a) with at least one washing medium;

- (c) removing the washing medium of step (b) by drying;
- (d) dry storage of the dried separation membrane of step (c); and
- (e) filtering a fluid containing biomolecules through the dried separation membranes, so as to separate the biomolecules.

5 To minimize the risk of microbial attack when water is used as the washing medium, the separation membrane is preferably dried to a water activity of about 40%. As used herein, the term "water activity" means the equilibrium partial pressure of water in the membrane relative to pure water at the same temperature. In step (b) above a strongly volatile organic substance of one or more components that are miscible with the washing 10 medium may be added as an impregnation medium which remains in the membrane during the drying stage. A film can be also formed on the surface of the pores or the membrane can be formed in a swollen state.

15 Referring to the drawings, wherein like numerals refer to the same elements, there is shown in FIG. 1 a filter module 1 for the separation of biomolecules from a fluid essentially comprising a housing 2, a membrane 3 having a membrane body 4, an inlet 5 and an outlet 6. Membrane body 4 is microporous and adsorptive and may be made from CA, CN, polyamide, PES, PP or PVDF with an average pore diameter of from 0.01 to 15  $\mu\text{m}$ , preferably 0.2 to 5  $\mu\text{m}$ . Membrane body 4 is preferably planar and has a thickness from 100 to 500  $\mu\text{m}$ , more preferably from 200 to 300  $\mu\text{m}$ . Affinity ligands of the types previously 20 described are coupled to membrane body 4, and are selected so that they have the capability to interact with the biomolecules to be separated from the processed liquid.

Although membrane body 4 can be provided as a single layer arranged in housing 2 as shown in FIG. 1, multiple housings, each provided with a membrane body 4' can be arranged in series, as shown in FIG. 2.

25 It is also possible to arrange membranes 3"/membrane bodies 4" in several layers in one housing 2", as shown in FIG. 3. Membrane bodies are preferably impregnated with glycerine and then subjected to drying, so as to remove water to a very high degree. After dry storage or after transport, the fluid containing biomolecule(s) for processing is supplied through inlet 5 and transported convectively through the membranes, thereby 30 binding the biomolecules to be separated to the affinity ligands. Filtered fluid is discharged through outlet 6.

## Example

A phosphate buffered saline (PBS) solution having a pH of  $7.3 \pm 0.2$  was prepared as described by J. Sambrook et al. in "Molecular Cloning – A Laboratory Manual," Book 3, Appendix b. 12 (2d ed. 1989) by combining the following components in the 5 concentrations noted in an aqueous solution.

10

Concentration (g/L)	Substance
8.00	NaCl
0.20	KCl
1.44	Na <sub>2</sub> HPO <sub>4</sub>
0.24	KH <sub>2</sub> PO <sub>4</sub>

Three 25 mm disks of a regenerated cellulose microporous membrane functionalized with aldehyde groups (Sartobind® Aldehyde Membrane Code 19306) were reacted with Protein A which contains primary amine groups (Repligen Company, 15 Designation rPrA, Lot No. 011038) to form a Protein A affinity ligand coupled via aldehyde/amine chemical links to the membranes. The protein was dissolved in 10 mg/mL of the PBS solution. The three membrane disks were placed in a Petri dish with 2 mL of the Protein A/PBS solution and agitated for three hours at ambient temperature to form reversible Schiff bases from the aldehyde/amine links. The so-formed Schiff bases were reduced by the 20 addition of 10 mg/mL sodium cyanoborohydrate. After the reaction took place, the membranes were removed and transferred to a fresh Petri dish. In order to reduce the remaining aldehyde groups, 5 mL of a solution of sodium borohydride in PBS with a final concentration of 1% was added to the membranes and the same were agitated for another 15 minutes. The membranes were then washed sequentially with the following solutions: PBS; 25 0.1 M glycine, adjusted to pH 2.7 with HCl; 1 mM HCl in water; 1 mM NaOH in water; and 1 mM NaCl in 0.01 M potassium phosphate, pH 7.0. The membranes were then dried at ambient temperature with an air current for 3 hours and stored at 4°C while air was substantially excluded.

30 The membranes were removed from storage after the storage times noted in the table below and tested with respect to their binding capacity for human immunoglobulin of the type IgG1 and IgG2. Filtration modules for the tests were made by incorporating three

of the membranes described above into a syringe adaptor unit with a diameter of 25 mm and equipped with a disposable syringe (both from Sartorius AG).

Processed human plasma from a local blood bank was diluted with PBS to a ratio of 1 : 40 and this solution was first filtered through a 0.2  $\mu\text{m}$  membrane. The syringe 5 was filled with 10 mL of the pre-filtered solution and gravity filtration with the Protein A-coupled membranes was carried out. Following this filtration, washing was conducted with 10 mL of PBS and the bound IgG was eluted with 10 mL of 0.1 M glycine, pH 2.7. The absorption of the elution solution was determined at 280 nm with a spectrum photometer and a manually adjustable calibration apparatus using bovine serum albumin (BSA) as a control 10 to determine the protein-binding capacity. The IgG binding capacity of the functionalized membranes for Protein A as a function of time for these tests are shown in the table below. All values were median values obtained with at least 2 measurements.

Time (Days)	Binding Capacity ( $\mu\text{g}/\text{cm}^2$ )
0	42
1	41
4	47
20	43
45	40
56	37

15 The terms and expressions which have been employed in the foregoing specification are used therein as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding equivalents of the features shown and described or portions thereof, it being recognized that the scope of the invention is defined and limited only by the claims which follow.